Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFAKGR)

• Drug Name: CG-400549 Drug Info
• Synonyms: CG-400329; CG-400462; CG-400587; Bacterial enoyl-ACP reductase inhibitors, CrystalGenomics; FabI inhibitors (antibacterial), CrystalGenomics; FabK inhibitors (bacterial infections, oral), CrystalGenomics

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 11844916
  CAS Number: CAS 934628-27-0
  TTD Drug ID: DMFAKGR

Molecule-Related Drug Atlas

Drug(s) Targeting Staphylococcus Enoyl ACP reductase (Stap-coc fabI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AFN-1252	DMTFE9Y	Staphylococcus infection	1B5Y	Phase 2	[3]
Afabicin	DMFO2G5	Acute bacterial skin infection	1C41	Phase 2	[4]
MUT-056399	DMC3NSK	Methicillin-resistant staphylococci infection	1A00-1A09	Preclinical	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Staphylococcus Enoyl ACP reductase (Stap-coc fabI)	TTZBRVL	FABI_STAA8	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT01593761) Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus. U.S. National Institutes of Health.
• [2] In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3.
• [3] Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7.